GemVax & KAEL
082270 · KOSDAQ · South Korea
Public Market Listing
082270KOSDAQ
Live quotes, historical charts, and market capitalization for GemVax & KAEL are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Telomerase (hTERT)Peptide | Alzheimer's DiseasePancreatic Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $12M | $1.6M | $15M | $2.0M | report ↗ |
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | $18M | $1.2M | $11M | $1.4M | report ↗ |
| 2025-Q3 | $13M | $1.4M | $9.1M | $6.3M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $57M | $10M | $11M | $12M | report ↗ |
GemVax & KAEL reported revenue of $57.36M, up 24.5% YoY, R&D spend of $10.13M, down 60.7% YoY, cash and equivalents of $11.43M, and a quarterly net burn of $12.11M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text